This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read BioAtla’s 8K filing here.
BioAtla Company Profile
BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.
See Also
- Five stocks we like better than BioAtla
- Retail Stocks Investing, Explained
- Opal Fuels CEO on Steering the Future of Renewable Natural Gas
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- MicroStrategy Joins Nasdaq-100: 2 Crypto Stocks Set to Win
- ETF Screener: Uses and Step-by-Step Guide
- 2 Underrated Quantum Computing Companies Starting to Rally
